Severance for Small Cap Biotechs

posted in: Plan Design, Uncategorized | 0

We recently performed severance analyses for about 40 public companies with market caps below $1 billion. The group was mostly comprised of drug development companies without substantial revenues but there were a few device and service health care companies–also without substantial revenues. The results were pretty similar regardless of our snapshots. Reproduced below is a summary of the findings. For more info please feel free to call at 650-862-1664.


Leave a Reply